SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and ...

Second Quarter 2021 and Recent Corporate Highlights Initiated global Phase 2 ARTEMIS-UC clinical trial of PRA023 in Ulcerative Colitis (UC). Prometheus’ Phase 2 ARTEMIS-UC clinical trial is currently ...

- APOLLO-CD Phase 2a along with ARTEMIS-UC Phase 2 topline results expected in fourth quarter 2022 - - Final Phase 1a results for PRA023 in normal healthy volunteers expected in fourth quarter 2021- ...

Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, raised the proposed deal size for its upcoming IPO on Thursday. The San Diego, CA-based ...

The developers of the popular Prometheus monitoring tool announced a new operating mode for the software today that’s designed to run more efficiently in low-resource environments such as edge ...

The Technology Association of Iowa is pleased to announce the winners of the 2021 Prometheus Awards Presented by LWBJ. The Prometheus Awards were celebrated on Thursday in downtown Des Moines. The ...

-PRA023, an anti-TL1A mAb, on track to initiate Phase 2 study for Ulcerative Colitis and Phase 2a study for Crohn’s Disease in 3Q 2021- -Launched Prometheus Enroll360™, a global patient recruitment ...

- Topline results for ongoing Phase 2 clinical trial in ulcerative colitis and Phase 2a trial in Crohn’s disease expected in fourth quarter 2022 - - Phase 2 trial in Systemic Sclerosis ...